Spark Therapeutics has announced (pdf) it completed raising $72.8 million in series B financing.
Spark Therapeutics, headquartered in Philadelphia, is a late-stage company developing gene-based medicines for a wide range of diseases.
The financing round was led by Sofinnova Ventures. Joining Sofinnova as new investors are Brookside Capital, Deerfield Management Company, Rock Springs Capital, funds and accounts managed by T. Rowe Price Associates, Wellington Management Co. and two undisclosed dedicated healthcare funds. The Children’s Hospital of Philadelphia, a co-founder of the company, also participated significantly in the round.
Spark indicated the funds would be used to advance the company’s pipeline of gene therapy programs, including development of its lead phase 3 program to address RPE65-related retinal dystrophies, and support the company’s growth over the next three years.